Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Context Therapeutics Inc.: Reduced quorum to one-third, eliminated stockholder list requirement, updated notice requirements for director nominations and proposals, and implemented procedural mechanisms related to Rule 14a-19 (effective 2024-03-19).
- Change
- bylaw amendment
- Effective
- 2024-03-19
Exact text from the filing
On March 19, 2024, the Board of Directors of the Company approved the amendment and restatement of the Company's Amended and Restated Bylaws (as so amended and restated, the “Bylaws”), primarily to (i) reduce the quorum necessary to hold a meeting of stockholders to one-third of the Company's capital stock issued and outstanding and entitled to vote, present in person or represented by proxy, (ii) eliminate the requirement to produce and keep a stockholder list for examination at each meeting of stockholders, (iii) update notice requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at stockholder meetings (other than proposals to be included in the Company’s proxy materials pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) and (iv) implement certain procedural mechanisms related to stockholder nominations of directors under Rule 14a-19 (“Rule 14a-19”) under the Exchange
View on SEC.gov